PE Tech Report


Like this article?

Sign up to our free newsletter

Delphinus appoints two new board members

Delphinus Medical Technologies has added two new senior-level advisors to its Board of Directors.

With more than 35 years of combined experience with emerging healthcare innovators, John Neis and Michael Fulton, MD, will help guide the company as it develops commercialisation plans for SoftVue, the firm’s whole breast ultrasound system that allows physicians to image the entire breast for diagnostic imaging purposes.
The appointments cap off Delphinus’ Series C venture round, which garnered more than USD39 million. This unprecedented venture capital funding is the single largest amount ever raised for a healthcare imaging company in the Midwest, as well as the largest for a medical device company in Michigan.
“We are extremely fortunate to be able to add John and Mike to our already-prestigious board,” says Mark J Forchette, president and CEO of Delphinus. “Their experiences guiding medical device companies to success will be invaluable as we introduce SoftVue.”
Neis is a managing director at Venture Investors LLC, which focuses on opportunities emerging from leading research universities in the Midwest. He currently serves on the boards of several other healthcare companies, and he is a member of the board of the Wisconsin Technology Council, the science and technology advisor to the state’s governor and legislature. He also serves on the Dean’s Advisory Board and the Weinert Applied Ventures Program Advisory Board in the School of Business and chairs the Tandem Press Advisory Board in the School of Education at the University of Wisconsin – Madison. Neis, a chartered financial analyst, received a Bachelor of Science degree in finance from the University of Utah, and a Master of Science degree in marketing and finance from the University of Wisconsin – Madison.
“I am very pleased to join the Delphinus board to work together to bring this life saving technology to the market,” says Neis. “Delphinus and its SoftVue technology address a significant need in the breast cancer diagnostic continuum, especially for women who have dense breast tissue.”
Fulton, a managing director at Hopen Life Science Ventures, has spent his entire career in the life sciences space, including 18 years as a successful investor and entrepreneur. Prior to joining Hopen, he served in the roles of founder, director, and CEO at a number of healthcare companies, including Lanx, Inc, (purchased by Biomet), and ProNerve, LLC (purchased by a private equity firm). Fulton is an inventor of multiple medical devices, and holds more than 50 U.S. and international patents. He received his Bachelor of Arts degree from Northwestern University, his medical degree from Cornell University Medical College, and completed two years of neurosurgery residency at the Cleveland Clinic.
“SoftVue represents a breakthrough technology designed to provide tissue characterisation based on the capture of transmission signals only possible due to its unparalleled ring transducer design,” Fulton adds. “We anticipate this will both increase breast cancer detection and reduce false positives, particularly for women with dense breasts. I am pleased to join this talented team.”

Like this article? Sign up to our free newsletter